Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the teamsta severe htn study

The Journal of Clinical Hypertension, 04/27/2012

Treatment of patients with substantially elevated blood pressure (SBP) with telmisartan/amlodipine (T/A) single–pill combinations (SPCs) resulted in high and significantly greater BP reductions and higher BP goal and response rates than the respective monotherapies. T/A SPCs were well tolerated.


  • This 8–week, randomized, double–blind, controlled study.
  • Compared efficacy and tolerability of telmisartan/amlodipine (T/A) single–pill combination (SPC) vs the respective monotherapies in 858 patients with severe hypertension (systolic/diastolic blood pressure [SBP/DBP] ≥180/95 mm Hg).
  • At 8 weeks, T/A provided significantly greater reductions from baseline in seated trough cuff SBP/DBP (–47.5 mm Hg/–18.7 mm Hg) vs T (P<.0001) or A (P=.0002) monotherapy; superior reductions were also evident at 1, 2, 4, and 6 weeks.


  • Blood pressure (BP) goal and response rates were consistently higher with T/A vs T or A.
  • T/A was well tolerated, with less frequent treatment–related adverse events vs A (12.6% vs 16.4%) and a numerically lower incidence of peripheral edema and treatment discontinuation.

Print Article Summary Cat 2 CME Report